Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

ArriVent BioPharma (AVBP) Preferred Shares Issued (2023)

ArriVent BioPharma has reported Preferred Shares Issued over the past 1 years, most recently at -$24000.0 for Q2 2023.

  • Quarterly results put Preferred Shares Issued at -$24000.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $44.9 million (changed N/A YoY), and the annual figure for FY2023 was $44.9 million, changed.
  • Preferred Shares Issued reached -$24000.0 in Q2 2023 per AVBP's latest filing, down from $44.9 million in the prior quarter.
  • Across five years, Preferred Shares Issued topped out at $44.9 million in Q1 2023 and bottomed at -$24000.0 in Q2 2023.